Open AccessRecent therapeutic targets in diabetic nephropathy
Author(s) -
Mohsen Marwa,
Elberry Ahmed A.,
Mohamed Rabea Alaa,
Abdelrahim Mohamed E. A.,
Hussein Raghda R. S.
Publication year - 2021
Publication title -
international journal of clinical practice
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.756
H-Index - 98
eISSN - 1742-1241
pISSN - 1368-5031
DOI - 10.1111/ijcp.14650
Subject(s) - medicine , diabetic nephropathy , diabetes mellitus , disease , nephropathy , pathophysiology , intensive care medicine , kidney disease , bioinformatics , endocrinology , biology
Background The prevalence of diabetes mellitus has been increased dramatically which in turn leads to complications including cardiovascular diseases, diabetic kidney disease, and substantially end‐stage renal disease. Methods We reviewed articles discussing the pathophysiology of diabetic nephropathy with new agents that may be useful in the management of the disease. We used PubMed, Scopus, Google Scholar and the Open‐access searching engines. Results The recent recommendations primarily depend on glycaemic and blood pressure control and the use of standard renin‐angiotensin system blockade. Currently, the use of agents with nephroprotective effects beyond the hyperglycaemic lowering effect has been evidenced clinically. Conclusions In his review, the pathophysiology, clinical manifestations, and lines of treatment of diabetic nephropathy are discussed. In addition, a focus on the clinical role and nephroprotective effects of the emerging therapeutic class, dipeptidyl peptidase IV (DPP‐4) inhibitors, is addressed in detail.